Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 1
1973 2
1975 1
1976 2
1977 1
1978 1
1980 1
1982 1
1983 2
1984 5
1985 4
1986 11
1987 11
1988 6
1989 11
1990 11
1991 13
1992 13
1993 15
1994 17
1995 14
1996 19
1997 18
1998 27
1999 33
2000 23
2001 23
2002 37
2003 25
2004 30
2005 34
2006 65
2007 58
2008 56
2009 64
2010 44
2011 82
2012 79
2013 76
2014 92
2015 109
2016 106
2017 103
2018 77
2019 83
2020 95
2021 114
2022 95
2023 75
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,694 results

Results by year

Filters applied: . Clear all
Page 1
Essential thrombocythemia: challenges in clinical practice and future prospects.
Godfrey AL, Green AC, Harrison CN. Godfrey AL, et al. Blood. 2023 Apr 20;141(16):1943-1953. doi: 10.1182/blood.2022017625. Blood. 2023. PMID: 36379024 Free article. Review.
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular pathogenesis and which patients may have greatest risk of progression or vascular events. ...
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding t …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculat …
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by …
Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Klampfl T, et al. N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10. N Engl J Med. 2013. PMID: 24325356 Free article.
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). ...Among patie …
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in th …
Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P, Vannucchi AM. Guglielmelli P, et al. Blood Rev. 2020 Jul;42:100714. doi: 10.1016/j.blre.2020.100714. Epub 2020 Jun 3. Blood Rev. 2020. PMID: 32546373 Review.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukem …
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of …
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.
Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Barosi G, et al. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16. Blood. 2013. PMID: 23591792 Free PMC article.
Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV) issued in …
Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agen …
Myeloproliferative disorders.
Meier B, Burton JH. Meier B, et al. Emerg Med Clin North Am. 2014 Aug;32(3):597-612. doi: 10.1016/j.emc.2014.04.014. Epub 2014 Jun 7. Emerg Med Clin North Am. 2014. PMID: 25060252 Review.
Top advances of the year: Myeloproliferative neoplasms.
Bhave RR, Mesa R, Grunwald MR. Bhave RR, et al. Cancer. 2023 Dec 1;129(23):3685-3691. doi: 10.1002/cncr.35028. Epub 2023 Sep 28. Cancer. 2023. PMID: 37768996
In the past year, there have been several advances in MF, PV, and essential thrombocythemia. In MF, investigational approaches are focusing on strategies to optimize inhibition of signal transduction (including JAK inhibition), modify epigenetics, enhance apoptosis, …
In the past year, there have been several advances in MF, PV, and essential thrombocythemia. In MF, investigational approaches …
Essential thrombocythemia.
Harrison CN, Green AR. Harrison CN, et al. Hematol Oncol Clin North Am. 2003 Oct;17(5):1175-90, vii. doi: 10.1016/s0889-8588(03)00082-0. Hematol Oncol Clin North Am. 2003. PMID: 14560781 Review.
Essential thrombocythemia is a distinct clinical entity within the spectrum of myeloproliferative disorders. There is as yet no pathognomonic diagnostic test, and patients who currently fall into the category of essential thrombocythemia are likely to …
Essential thrombocythemia is a distinct clinical entity within the spectrum of myeloproliferative disorders. There is as yet n …
Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Iurlo A, Bucelli C, Cattaneo D. Iurlo A, et al. Curr Treat Options Oncol. 2023 Jul;24(7):802-820. doi: 10.1007/s11864-023-01099-8. Epub 2023 May 17. Curr Treat Options Oncol. 2023. PMID: 37195587 Review.
Current treatment of essential thrombocythemia (ET) should primarily prevent thrombo-hemorrhagic events, without increasing the rate of fibrotic progression or leukemic evolution, and secondarily control microvascular symptoms. ...
Current treatment of essential thrombocythemia (ET) should primarily prevent thrombo-hemorrhagic events, without increasing th …
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Vannucchi AM, Guglielmelli P, Tefferi A. Vannucchi AM, et al. Curr Opin Hematol. 2018 Mar;25(2):112-119. doi: 10.1097/MOH.0000000000000402. Curr Opin Hematol. 2018. PMID: 29194068 Review.
SUMMARY: The revised 2017 WHO classification of polycythemia vera and essential thrombocythemia allows early diagnosis and accurate distinction from other chronic myeloproliferative neoplasms, particulary prefibrotic myelofibrosis. The prognostic value of selected m …
SUMMARY: The revised 2017 WHO classification of polycythemia vera and essential thrombocythemia allows early diagnosis and acc …
1,694 results